최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국생물공학회지 = Korean journal of biotechnology and bioengineering, v.23 no.4, 2008년, pp.303 - 310
이동혁 (한남대학교 생명.나노과학대학 생명과학과) , 김찬경 (한남대학교 생명.나노과학대학 생명과학과) , 김태은 (한남대학교 생명.나노과학대학 생명과학과) , 김인섭 (한남대학교 생명.나노과학대학 생명과학과)
Bovine blood, cell, tissue, and organ are used as raw materials for manufacturing biologics such as biopharmaceuticals, tissue-engineered products, and cell therapy. Manufacturing processes for the biologics have the risk of viral contamination. Therefore viral validation is essential in ensuring th...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Yarlagadda, P. K., M. Chandrasekharan, and J. Y. Shyan (2005), Recent advances and current developments in tissue scaffolding, Biomed. Mater. Eng. 15, 159-177
Schneider, G . (2003), B ioim plants-characteristics and use, Laryngorhinootologie 82, 839-852
Erickson, G. A., S. R. Bolin, and J. G. Landgraf (1991), Viral contamination of fetal bovine serum used for tissue culture: risks and concerns, Dev. Biol. Stand. 75, 173-175
Faraj, K. A., T. H. van Kuppevelt, and W. F. Daamen (2007), Construction of collagen scaffolds that mimic the three-dimensional architecture of specific tissues, Tissue Eng. 13, 2387-2394
Rudnick, A. (2006), Advances in tissue engineering and use of type 1 bovine collagen particles in wound bed preparation, J. Wound Care 15, 402-404
Gajiwala, K. and A. L. Gajiwala (2004), Evaluation of lyophilised, gamma-irradiated amnion as a biological dressing, Cell Tissue Bank 5, 73-80
Horaud, F. (1991), Introductory remark: viral safety of biologicals, Dev. Biol. Stand. 75, 3-7
Parkman, P. D. (1996), Safety of biopharmaceuticals: a current perspective, Dev. Biol. Stand. 88, 5-7
Merten, O.-W. (2002), Virus contamination of cell culture-a biotechnological view, Cytotechnol. 39, 91-116
Celis, P. and G. Silvester (2004), European regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products, Dev. Biol. Stand. 118, 3-10
International Conference on Harmonisation (1998), Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability, Federal Resister 63, 51074-51084
Ryu, S.-R., J.-H. Shin, S.-Y. Baek, J.-O. Kim, K.-I. Min, B.-S. Min, B.-G. Kim, D.-K. Kim, M.-K. Park, M.-J. Ahn, K.-S. Chae, H.-S. Jeong, S.-H. Lee, and S.-N. Park (2003), Evaluation of limit of detection and range of quantitation for RT-PCR, real-time RT-PCR and RT-PCR-ELISA detection of bovine viral diarrhea virus contamination in biologics derived from cell cultures, J. Bacteriol. Virol. 33, 161-168
Jennings, A. (1999), Detecting viruses in sera: methods used and their merits, Dev. Biol. Stand. 99, 51-59
Jeong, H.-S., J,-H. Shin, Y.-N. Park, J.-Y. Choi, Y.-L. Kim, B.-G. Kim, S.-R. Ryu, S.-Y. Baek, S.-H. Lee, and S.-N. Park (2003), Development of real-time RT-PCR for evaluation of JEV clearance during purification of HPV type 16 L1 virus-like particles, Biologicals 31, 223-229
Minor, P. D. (1996), Mammalian cells and their contaminants, Dev. Biol. Standard. 88, 25-29
Collins, P. L., R. M. Chanock, and K. McIntosh (1996), Parainfluenza Viruses, In Virology, 3rd ed., Vol. 1, B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus, Eds., p1205, Fields Lippincott-Raven Publishers, Philadelphia
Eloit, M. (1999), Risks of virus transmission associated with animal sera or substitutes and methods of control, Dev. Biol. Stand. 99, 9-16
Assaf, R., C. Montpetit, and G. Marsolais (1983), Serology of bovibe parainfluenza virus type 3: comparison of the enzyme linked immunosorbent assay and hemagglutination inhibition, Can. J. Comp. Med. 47, 140-142
Kil, T. G., W. J. Kim, D. H. Lee, Y. Kang, H. M. Sung, S. H. Yoo, S.-N. Park, and I. S. Kim (2005), Quantitative real-time PCR of porcine parvovirus as a model virus for cleaning validation of chromatography during manufacture of plasma derivatives, Kor. J. Microbiol. 41, 216-224
Darling, A. (2002), Validation of biopharmaceutical purification process for virus clearance evaluation, Mol. Biotechnol. 21, 57-83
Adamson, S. R. (1999), Experiences of virus, retrovirus and retrovirus-like particles in chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics, Dev. Biol. Stand. 93, 89-96
Garnick, R. L. (1998), Raw materials as a source of contamination in large-scale cell culture, Dev. Biol. Stand. 93, 21-29
Code of federal regulation 9 (9CFR), animal and animal products (1996), Part 113.53. Requirement for ingredients of animal origin used for production of biologics
※ AI-Helper는 부적절한 답변을 할 수 있습니다.